Drug Approval | December 28, 2021
Sun Pharma receives DCGI approval for Molxvir in India
The product is expected to be available in a week’s time
The product is expected to be available in a week’s time
DCGI approved the drug based on the review of clinical data
The company will market it under the brand name Molflu
The drug will be marketed under the brand name Molnaflu
He has over 22 years of experience in pharmaceutical sales & business development
The U.S. FDA advisory committee voted 13-10 in favour of the oral antiviral medicine
The Drug Controller General of India (DCGI), is reviewing clinical data of molnupiravir for the treatment of Covid-19 in adults in India
Molnupiravir is an investigational oral antiviral medicine, for the treatment of mild-to-moderate COVID-19 in at risk adults
Applications remain under review by others including U.S. Food and Drug Administration and the European Medicines Agency
Cortrophin gel is purified corticotropin (ACTH), an important treatment option for patients struggling with certain chronic autoimmune disorders. It acquired the NDA for cortrophin gel from Merck & Co. in 2016
Subscribe To Our Newsletter & Stay Updated
